Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Myeloproliferative diseases.

M N Silverstein

    Postgraduate Medicine
    |February 1, 1977
    PubMed
    Summary

    Agnogenic myeloid metaplasia, a common myeloproliferative disease in older adults, has a 58% five-year survival rate. Prognosis is influenced by symptoms, anemia, thrombocytopenia, and liver size, with androgen therapy and splenectomy as potential treatments.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    A clinical update in polycythemia vera and essential thrombocythemia.

    The American journal of medicine·2000
    Same author

    Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients.

    Blood·2000
    Same author

    Treatment of polycythaemia vera and essential thrombocythaemia.

    Bailliere's clinical haematology·2000
    Same author

    Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995.

    American journal of hematology·1999
    Same author

    Treatment of essential thrombocythemia with anagrelide.

    Seminars in hematology·1999
    Same author

    Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia.

    British journal of haematology·1998

    Area of Science:

    • Hematology
    • Oncology

    Background:

    • Myeloproliferative diseases encompass a range of disorders with varying clinical presentations and outcomes.
    • Agnogenic myeloid metaplasia is the most prevalent among these, predominantly affecting the elderly population.

    Purpose of the Study:

    • To outline the clinical characteristics, prognostic factors, and therapeutic approaches for agnogenic myeloid metaplasia.
    • To provide insights into the management of anemia and potential surgical interventions.

    Main Methods:

    • Retrospective analysis of patient data.
    • Evaluation of survival rates and prognostic indicators.
    • Review of therapeutic interventions, including androgen therapy and splenectomy.

    Main Results:

    • The five-year survival rate for agnogenic myeloid metaplasia patients at the Mayo Clinic is 58%.
    • Prognosis is significantly correlated with the presence of symptoms, anemia, thrombocytopenia, and liver size.
    • Androgen therapy is frequently required for anemia management, and splenectomy may be indicated.

    Conclusions:

    • Agnogenic myeloid metaplasia presents a significant therapeutic challenge with a guarded prognosis.
    • Early identification of prognostic factors is crucial for patient management.
    • Treatment strategies should be individualized based on disease severity and patient-specific factors.

    Related Experiment Videos